Premium
In vivo Localisation of Human Urinary Bladder Carcinoma Xenograft in Nude Mice Using Radiolabeled Monoclonal Antibody
Author(s) -
YÜ D. S.,
YEH M. Y.,
CHEN W. L.,
CHANG S. Y.,
MA C. P.,
HAN S. H.
Publication year - 1987
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1987.tb04873.x
Subject(s) - monoclonal antibody , immunoscintigraphy , in vivo , antibody , urinary bladder , pathology , antigen , carcinoma , radioimmunotherapy , nude mouse , urinary system , medicine , transitional cell carcinoma , cancer research , chemistry , biology , immunology , bladder cancer , cancer , microbiology and biotechnology
Summary— Monoclonal antibody 1G3.10 (mouse lgG3) against the human urinary bladder carcinoma TSGH‐8301 was isolated from hybridoma ascites and labelled with radioiodine. The antibody reacts with a cell surface antigen preferentially expressed in human bladder carcinoma. Binding studies in vitro demonstrated that its specificity for antigen was retained after iodination. The clearance of the radiolabeled monoclonal antibody was not modified by the presence of the tumour. In vivo localisation of the radiolabeled antibody and control normal IgG to tumour xenograft was determined by counting the tissue radioactivity and by external gamma ray scintigraphy with computer analysis of the region of interest at various times after the intravenous injection of radiolabeled antibodies. Maximum tumour‐to‐blood radioactivity (4.5) was obtained 4 days after antibody injection. There was no tumour localisation of radiolabeled normal IgG. Specificity of the localisation was also confirmed by using a non‐reactive colon carcinoma xenograft. Distinct tumour images were obtained without the use of subtraction techniques. These studies of human bladder tumour localisation using this monoclonal antibody show its obvious potential for clinical use.